Esperion Therapeutics | ESPR - Assets


Esperion Therapeutics reported $465.89M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amarin USD 645.76M 25.01M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cipla INR 401.64B 27.77B Sep/2025
CSL USD 37.9B 1.5B Dec/2025
Cytokinetics USD 1.27B 151.06M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Geron USD 570.54M 3.16M Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 11.49B 850M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025